[Results and current biological bases of therapy of malignant hemoreticulopathies].
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use; D003348:Cortisone / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D008466:Mechlorethamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010954:Plasmacytoma / Q000188:drug therapy*; D011086:Polycythemia / Q000188:drug therapy*; D014747:Vinblastine / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy*
D000970:Antineoplastic Agents; D006834:Hydrazines; D002699:Chlorambucil; D008466:Mechlorethamine; D014747:Vinblastine; D003520:Cyclophosphamide; D003348:Cortisone; D008727:Methotrexate
Rezultate şi baze biologice actuale ín terapia hemoreticulopatiilor maligne.